Retatrutide

Retatrutide is a novel triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. This triple-agonist approach represents the next generation of metabolic research compounds. Phase 2 clinical trials demonstrated weight reductions of up to 24% over 48 weeks at the highest dose level. Retatrutide's unique triple mechanism of action addresses multiple metabolic pathways simultaneously, making it a significant advancement in metabolic research.

Unlike dual agonists, Retatrutide adds glucagon receptor activation which may enhance energy expenditure and fat oxidation beyond what GLP-1/GIP dual agonism achieves alone. This compound is for research purposes only.